Mark Lythgoe, Clinical Research Fellow in Oncology therapy/drug development at Imperial College London, shared a post on X:
“The march on subcutaneous immunotherapy continued with the FDA approval of SC pembrolizumab – will this significantly improve access or is it just patent evergreening?”
More posts featuring Mark Lythgoe.